Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases

Cancer Research

Volumn 72, Issue 1, 2012, Pages 271-281

  Huang, Gangxiong ^a   Yu, Ling ^a   Cooper, Laurence J N ^a   Hollomon, Mario ^a   Huls, Helen ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 11 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL KILLING; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; EX VIVO STUDY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; ELECTROPORATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OSTEOSARCOMA; PLASMIDS; T-LYMPHOCYTES;

EID: 84855410248     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2778     Document Type: Article

References (42)

1. Jaffe N.Chemotherapy in osteosarcoma: advances and controversies. In: Muggia FM, editor. Experimental and clinical progress in chemotherapy. Boston, MA: Martinus Nijhoff Publishers; 1986. p. 223-33.
2. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Balasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of extremity. N Engl J Med 1986;314:1600-6. (Pubitemid 16118216)
3. Eiber F, Giuliano A, Echardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6. (Pubitemid 17007852)
4. Goorin AM, Perez Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/The Children's Hospital-Study III. J Clin Oncol 1987;5:1178-84. (Pubitemid 18045302)
5. Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, et al. Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol 1990;8:1988-97.
6. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcome R, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
7. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983;43:2010-4. (Pubitemid 13088732)
8. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995;18:93-9.
9. Meyers PA, Schwartz C, Krailo M, Healey JH, Bernstein M, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children's Oncology Group. J Clin Oncol 2008;26:119-26.
10. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010;116:1035-44.
11. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004;33:83-9. (Pubitemid 38829603)
12. Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 2001;158:25-32. (Pubitemid 32096467)
13. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and pg 130. Blood 1995;86:1243-54.
14. Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, Strater J, et al. Functional expression of the interleukin-11 receptor alphachain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem 2004;279:10304-15. (Pubitemid 38372637)
15. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effect of interleukin-11. Leukemia 1999;13:1307-15. (Pubitemid 29429755)
16. Teramura M, Kobayashi S, Yoshinaga K, Iwabe K, Mizoguchi H. Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 1996;38:99-102.
17. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004;64:435-9. (Pubitemid 38120878)
18. Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol 2006;13:802-8. (Pubitemid 43727364)
19. Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, Uemura T, et al. Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol 2007;30:825-33.
20. Lewis VO, Ozawa MG, Deavers MT, Wang G, Shinta T, Arap W. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models and human tumor samples. Cancer Res 2009;69:1995-9.
21. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999;6:501-6. (Pubitemid 30182744)
22. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008;68:2961-71. (Pubitemid 351556297)
23. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-27. (Pubitemid 34155122)
24. Heckman KL, Pease LR. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2007;2:924-932. (Pubitemid 46758810)
25. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011;71:3516-27.
26. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-18. (Pubitemid 46017932)
27. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-68. (Pubitemid 46224233)
28. Wang W, Ke S, Kwon S, Yallampalli S, Cameron AG, Adams KE, et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 2007;18:397-402. (Pubitemid 46493510)
29. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;15:10995-1004. (Pubitemid 44876999)
30. Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 2009;152:497-508.
31. Gordon N, Koshkina NV, Jia S-F, Khanna C, Mendoza A, Worth LL. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007;13:4503-10. (Pubitemid 47219720)
32. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role the Fas pathway in metastatic process of osteosarcoma. Mol Cancer Res 2007;10:991-9. (Pubitemid 350070755)
33. Posthumadeboer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011;28:493-503.
34. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 1993;53:4890-95. (Pubitemid 23326183)
35. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-7. (Pubitemid 351555543)
36. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010; 55:67-75.
37. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009;17: 1779-87.
38. Moore C, Eslin D, Levy A, Roberson J, Guisti V, Sutphin R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer 2010;55:1041-2.
39. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53.
40. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76. (Pubitemid 46871329)
41. Putnam JB Jr, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 1983;36:516-23. (Pubitemid 13022814)
42. Hawkins DS, Arndt CS. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447-56. (Pubitemid 37466660)